| Form of release | Blister (25 tablets), Pack (100 tablets) |
|---|---|
| International name | Andarine (S-4) |
| Chemical name | 4-((2S)-2-(3-chlorophenoxy)-N-(4-cyano-3-trifluoromethylphenyl)-3-hydroxy-2-methylpropanamide) |
| Type of drug combination | SARM (selective androgen receptor modulator) |
| Molecular formula | C19H18ClF3N2O3 |
| Molecular weight | 389,81 g/mol |
| Half-life | 4–6 hours |
| Mechanism of action | Selective binding to androgen receptors in muscles and bones, stimulating muscle growth and muscle preservation during calorie deficiency |
| Anabolic activity | Average |
| Androgenic activity | Low |
| Main effects | Muscle drying, maintaining lean mass during calorie deficit, improving muscle tone, moderate increase in strength |
| Side effects | Mild suppression of testosterone, temporary visual disturbances (yellow or green tint, decreased twilight vision), headaches, irritability |
| The necessity of PCT | Recommended for long-term courses (>6 weeks) |
| Recommended dosage | 25–50 mg per day |
| Course duration | 6–8 weeks |
| Reception hours | In the morning and before training |
| Impact on estrogens | No |
| Impact on the liver | Moderate |
| Impact on lipid profile | May lower HDL with prolonged use |
| Storage | In a dry, cool place, protected from light, at a temperature not exceeding 25°C |
| Use by women | Acceptable in small doses (5–10 mg), but with caution due to androgenic effects |
| Detection period in the body | Up to 2–3 weeks |